- Home
- MBRX vs GLTO Comparison
MBRX vs GLTO Comparison
Compare MBRX & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBRX | GLTO |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 23.7M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MBRX | GLTO |
|---|---|---|
| Price | $7.24 | $27.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $125.00 | $32.00 |
| AVG Volume (30 Days) | 105.9K | ★ 3.4M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.01 | $2.01 |
| 52 Week High | $91.25 | $33.60 |
Technical Indicators
Market Signals| Indicator | MBRX | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 89.96 | 72.53 |
| Support Level | $0.26 | $16.70 |
| Resistance Level | $7.75 | $29.03 |
| Average True Range (ATR) | 0.29 | 2.83 |
| MACD | 0.83 | 0.35 |
| Stochastic Oscillator | 93.19 | 96.77 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.